Anxa2 drives the function of immune suppressive neutrophils in lung cancer
Anxa2 驱动肺癌中免疫抑制性中性粒细胞的功能
基本信息
- 批准号:10310981
- 负责人:
- 金额:$ 4.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:ANXA2 geneAccountingAddressAnnexinsCD8-Positive T-LymphocytesCancer EtiologyCancer PatientCell LineageCessation of lifeClinicalClinical TrialsDataHumanImmuneImmune checkpoint inhibitorLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMyelogenousNon-Small-Cell Lung CarcinomaPD-1/PD-L1PhenotypePlayResearch PersonnelRoleScientistSpecimenTestingTrainingTumor-Derivedanti-PD-1anti-PD-L1 therapybasecancer typecareercell typecheckpoint therapycohortgraduate studentimmune checkpoint blockadeimmune functionimprovedneutrophilnovel therapeuticsskillssuccess
项目摘要
ABSTRACT
Although immune checkpoint inhibitor (ICI) therapy has been a tremendous clinical success, just ~20% of non-
small cell lung cancer (NSCLC) patients respond to anti-PD1/PDL1 therapy. In efforts to improve upon this figure,
the field has launched over 800 clinical trials (across all cancer types) testing novel therapeutics in conjunction
with immune checkpoint blockade. Unfortunately, such trials have been based largely on theoretical
considerations and not by data obtained from actual human cancer specimens. Notably, very few of these trials
address myeloid lineage cells and none of them address the neutrophil lineage. Our group recently undertook a
comprehensive immune phenotyping project to identify potential immune suppressive factors in human NSCLC.
We found that neutrophils were the most prevalent immune cell type out of the 51 immune cell types and
subtypes assessed. More importantly, the presence of neutrophil lineage cells inversely correlated with CD8+
lymphocyte content within the TME. Here, we will show tumor-derived Annexin-A2 polarizes neutrophils to an
immune suppressive phenotype and determine the mechanisms by which it does so. More importantly, this
project will provide the necessary training ground for the graduate student to obtain the skills and critical
examination of data to progress in his career towards an independent scientist.
摘要
尽管免疫检查点抑制物(ICI)治疗在临床上取得了巨大的成功,但只有~20%的非
小细胞肺癌(NSCLC)患者对抗PD1/PDL1治疗有反应。在努力改善这一数字时,
该领域已经启动了800多项临床试验(涉及所有癌症类型),测试联合使用的新疗法
有免疫检查站封锁。不幸的是,这样的试验在很大程度上是基于理论
考虑因素,而不是从实际的人类癌症样本中获得的数据。值得注意的是,这些试验中很少有
定位于髓系细胞,但无一定位于中性粒细胞。我们小组最近进行了一次
综合免疫表型项目以确定人类非小细胞肺癌潜在的免疫抑制因素。
我们发现,在51种免疫细胞类型中,中性粒细胞是最常见的免疫细胞类型,
评估的亚型。更重要的是,中性粒细胞系细胞的存在与CD8+呈负相关
TME内的淋巴细胞含量。在这里,我们将展示肿瘤来源的Annexin-A2使中性粒细胞极化为
免疫抑制表型,并确定其作用机制。更重要的是,这
项目将为研究生提供必要的培训场地,以获得关键的技能和关键技能
为了在成为独立科学家的职业生涯中取得进步,他对数据进行了审查。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A McGarry Houghton其他文献
A McGarry Houghton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A McGarry Houghton', 18)}}的其他基金
Neutrophil derived proteinases abolish the IFNG signature in NSCLC
中性粒细胞衍生的蛋白酶消除 NSCLC 中的 IFNG 特征
- 批准号:
10717448 - 财政年份:2023
- 资助金额:
$ 4.02万 - 项目类别:
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
用于肺癌治疗联合临床成像的定量 PET/CT 研究资源
- 批准号:
10301566 - 财政年份:2021
- 资助金额:
$ 4.02万 - 项目类别:
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
用于肺癌治疗联合临床成像的定量 PET/CT 研究资源
- 批准号:
10700944 - 财政年份:2021
- 资助金额:
$ 4.02万 - 项目类别:
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC
项目1:靶向中性粒细胞谱系以增强非小细胞肺癌中免疫检查点抑制剂的功效
- 批准号:
10174872 - 财政年份:2019
- 资助金额:
$ 4.02万 - 项目类别:
Tumor-specific autoantibodies for SCLC early detection
用于 SCLC 早期检测的肿瘤特异性自身抗体
- 批准号:
10299616 - 财政年份:2019
- 资助金额:
$ 4.02万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 4.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 4.02万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 4.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 4.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 4.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 4.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 4.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 4.02万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 4.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 4.02万 - 项目类别: